• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals Product Image

Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals

  • ID: 2375861
  • December 2012
  • Region: United States
  • 205 Pages
  • Frost & Sullivan

Bowel Disorders Market is Buoyant and Poised for Growth

This research service is focused on the major bowel disorders and evaluates the market for oral and injectable prescription pharmaceuticals for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This research service covers the U.S. market from 2009 to 2017, with 2011 as the base year. Included are products on the market, products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Disease-specific topics including definitions, diagnosis, disease assessment, and clinical treatment guidelines are also outlined and discussed.

Summary

Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent two families of bowel disorders with a common denominator of significant unmet medical need.

The two main indications comprising IBD are Crohn’s disease (CD) and ulcerative colitis (UC), each with distinct pathologies and therapeutic needs. While many drugs are effective for both CD and UC, the unique features of each disorder result in the differential and unpredictable efficacy READ MORE >

1. The U.S. Bowel Disorders Prescription Pharmaceuticals Market
- Analysis of the Bowel Disorders Prescription Pharmaceuticals Market in the U.S.
- - Executive Summary and Market Overview

2. Bowel Disorders Prescription Pharmaceuticals Market - Total Market
- Analysis of the Total Bowel Disorders Prescription Pharmaceuticals Market
- - Drivers and Restraints
- - Forecast and Trends
- - Demand Analysis
- - Market Share and Competitive Analysis

3. Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Analysis of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Segment Breakdown and Market Engineering Measurements
- Analysis of the 5-ASA Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Subsegment Breakdown and Market Engineering Measurements
- - Treated Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast
- - Market Share Analysis
- Analysis of the Corticosteroid Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Subsegment Breakdown and Market Engineering Measurements
- - Treated Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast
- - Market Share Analysis
- Analysis of the TNF Inhibitor Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Subsegment Breakdown and Market Engineering Measurements
- - Treated Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast
- - Market Share Analysis
- Analysis of the Non-TNF Biologicals Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Subsegment Breakdown and Market Engineering Measurements
- - Treated Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast
- Analysis of the Novel Orals Subsegment of the Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- - Subsegment Breakdown and Market Engineering Measurements
- - Treated Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast

4. Irritable Bowel Syndrome Prescription Pharmaceuticals Segment
- Analysis of the Irritable Bowel Syndrome Prescription Pharmaceuticals Segment
- - Segment Breakdown and Market Engineering Measurements
- - Patient Forecast
- - Pricing Trends and Forecast
- - Revenue Forecast

5. Summary and Conclusions
- Summary and Conclusions
- - The Last Word
- - Game-changing Strategies

6. Appendix

List of Figures

Market Overview
- Total Bowel Disorders Prescription Pharmaceuticals Market: Estimated Incidence and Prevalence of CD and UC, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Distinguishing Characteristics of CD and UC, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Diagnostic Procedures Used in the Differential Diagnosis of CD and UC, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Severity of Ulcerative Colitis Based on the Truelove and Witts Classification, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Severity of Crohn's Disease Based on the CDAI, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Common Disease Activity Assessment Instruments in Recent Phase 3 UC Trials, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Anatomic Extent of Ulcerative Colitis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Mild to Moderate UC), U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Severe UC), U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Mild-Moderate) CD, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Traditional Clinical Guidelines (Moderate-Severe CD), U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Modern Clinical Guidelines (Moderate-Severe CD), U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Rome III Diagnostic Criteria for IBS, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Examples of PRO Questions Used as Primary Endpoints in Past IBS Clinical Trials, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: General Clinical Trial Design Guidance for Sponsors of IBS Clinical Trials, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Trial Design Recommendations for Sponsors of IBS Clinical Trials, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011
- Total Irritable Bowel Syndrome Therapeutics Market: IBS Market Segmentation, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Indication, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011
External Challenges: Drivers and Restraints—Total Bowel Disorders Prescription Pharmaceuticals Market
- Total Bowel Disorders Prescription Pharmaceuticals Market: Key Market Drivers and Restraints, U.S., 2012–2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: Potential Revenue per Patient for Lifelong IBD Therapy Diagnosed in a Young Patient, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Selected Drugs Discontinued for Irritable Bowel Syndrome, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Selected Drugs Discontinued for Inflammatory Bowel Disease, U.S., 2011
Forecasts and Trends—Total Bowel Disorders Prescription Pharmaceuticals Market
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Prevalence and Treated Patient Forecast, U.S., 2009-2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Prevalence by Indication, U.S., 2009-2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Prevalence by Disease Severity and Forecast, U.S., 2009-2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Prevalence by Indication and Forecast, U.S., 2009-2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: Range of Reported Disease Prevalence Estimates, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Average Annual Cost of Therapy, U.S., 2009-2017
- Total Bowel Disorders Prescription Pharmaceuticals Market: Revenue Forecast, U.S., 2009-2017
Demand Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Penetration, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Penetration, U.S., 2011
Market Share and Competitive Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market
- Total Bowel Disorders Prescription Pharmaceuticals Market: Percent of Sales, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Absolute Market Share Trend, U.S., 2009-2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Market Share Trend, U.S., 2009-2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Company Market Share Analysis of Top Four Participants, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Competitive Structure, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Timeline of Key Events, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Product Profiles of Promising Late-stage Candidates, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Remission Rates in CD of Selected Marketed and Late-stage Drugs, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Remission Rates in UC of Selected Marketed and Late-stage Drugs, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Number of Drugs per Class by Stage of Development—Oral and Injectable Therapies for IBD, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Number of Drugs per Class by Stage of Development—Topical Therapies for IBD, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Number of IBD Drugs per Class by Stage of Development, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Marketed Product Analysis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Late-stage Product Analysis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Pipeline Analysis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: Number of IBS Drugs per Class by Stage of Development, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Marketed Product Analysis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Late-stage Product Analysis, U.S., 2011
- Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Pipeline Analysis, U.S., 2011
Inflammatory Bowel Disease Prescription Pharmaceuticals Segment
- Inflammatory Bowel Disease Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011
- Inflammatory Bowel Disease Prescription Pharmaceuticals Market: Percent Patient Share Breakdown by Drug Class, U.S., 2011
5-ASA Subsegment Breakdown
- 5-ASA Subsegment Percent Sales Breakdown, U.S., 2011
- 5-ASA Subsegment: Treated Patient Forecast, U.S., 2009-2017
- 5-ASA Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017
- 5-ASA Subsegment: Revenue Forecast, U.S., 2009-2017
- 5-ASA Subsegment: Percent of Sales, U.S., 2011
- 5-ASA Subsegment: Company Market Share Analysis of Top Two Participants, U.S., 2011
Corticosteroid Subsegment Breakdown
- Corticosteroid Subsegment Percent Sales Breakdown, U.S., 2011
- Corticosteroid Subsegment: Treated Patient Forecast, U.S., 2009-2017
- Corticosteroid Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017
- Corticosteroid Subsegment: Revenue Forecast, U.S., 2009-2017
- Corticosteroid Subsegment: Percent of Sales, U.S., 2011
- Corticosteroid Subsegment: Company Market Share Analysis of Participants, U.S., 2011
TNF Inhibitor Subsegment Breakdown
- TNF Inhibitor Subsegment: Percent Sales Breakdown, U.S., 2011
- TNF Inhibitor Subsegment: Treated Patient Forecast, U.S., 2009-2017
- TNF Inhibitor Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017
- TNF Inhibitor Subsegment: Revenue Forecast, U.S., 2009-2017
- TNF Inhibitor Subsegment: Percent of Sales, U.S., 2011
- TNF Inhibitor Subsegment: Company Market Share Analysis of Participants, U.S., 2011
Non-TNF Biologicals Subsegment Breakdown
- Non-TNF Biologicals Subsegment: Percent Sales Breakdown, U.S., 2011
- Non-TNF Biologicals Subsegment: Treated Patient Forecast, U.S., 2009-2017
- Non-TNF Biologicals Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017
- Non-TNF Biologicals Subsegment: Revenue Forecast, U.S., 2009-2017
Novel Orals Subsegment Breakdown
- Novel Orals Subsegment: Percent Sales Breakdown, U.S., 2011
- Novel Orals Subsegment: Percent Sales Breakdown, U.S., 2017
- Novel Orals Subsegment: Treated Patient Forecast, U.S., 2009-2017
- Novel Orals Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017
- Novel Orals Subsegment: Revenue Forecast, U.S., 2009-2017
Irritable Bowel Syndrome Segment Breakdown
- IBS Segment: Percent Sales Breakdown, U.S., 2011
- IBS Segment: Treated Patient Forecast, U.S., 2009-2017
- IBS Segment: Average Annual Cost of Therapy, U.S., 2009-2017
- IBS Segment: Revenue Forecast, U.S., 2009-2017

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos